Press release
December 21, 2010

Laurolactam capacity expansion successful

Evonik puts first phase of expansion into operation

Essen, Germany-based Evonik Industries has succeeded in implementing the expansion of its laurolactam capacity in Marl, as had been announced for the fourth quarter in May 2010. Laurolactam is the starting material for polyamide 12, which the Group markets as a construction material and as a powder: VESTAMID® and VESTOSINT®, respectively.

To ease the supply situation of polyamide 12-based molding compounds Evonik will further increase its laurolactam capacity as has been announced in November. In so doing, Evonik is strengthening its leading global market position in polyamide 12 and, as a reliable partner, is offering its customers supply security, both now and in the future.

Beginning with butadiene, Evonik produces laurolactam in a multi-step process and then polymerizes and compounds it to yield an extensive range of polyamide 12 products precisely customized to the requirements of processors and end users. Thanks to its properties, VESTAMID® applications run the gamut from sophisticated line systems for motor vehicles, through large-volume pipes used in crude oil production, wire insulation in the cable industry, and catheters in medical technology, to precision injection-molded parts such as pump impellers and control-valve housings in machine and equipment manufacture. VESTOSINT® is used to coat metal parts and wire products such as dishwasher racks.

About Evonik

Evonik Industries is the creative industrial group from Germany. In our core business of specialty chemicals, we are a global leader. In addition, Evonik is an expert in power generation from hard coal and renewable energies, and one of the largest private residential real estate companies in Germany. Our company’s performance is shaped by creativity, specialization, continuous self-renewal, and reliability.

Evonik is active in over 100 countries around the world. In its fiscal year 2009 about 39,000 employees generated sales of about €13.1 billion and an operating profit (EBITDA) of about €2.0 billion.


In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.